Management of Hyperglycemia in Type 2 Diabetes

Assessment and Treatment Approach

The American Diabetes Association recommends an HbA1c target of <7.0% for most nonpregnant adults with type 2 diabetes, and an HbA1c of 8.9% indicates suboptimal glycemic control requiring medication adjustment beyond monotherapy 1, 2
For patients with an HbA1c of 8.9%, intensification of therapy is required with dual or triple therapy to reduce the risk of microvascular and macrovascular complications 3, 4
The American College of Physicians recommends initiating dual therapy immediately rather than starting with monotherapy for treatment-naïve patients with an HbA1c >8.5% 5, 6
Metformin should be the foundation of therapy unless contraindicated, and a second agent should be added based on patient-specific factors and comorbidities 1, 2, 7

The American Association of Clinical Endocrinologists recommends adding a second agent to the current regimen for patients already on monotherapy, maintaining metformin if already prescribed 2, 6
Options for the second agent include sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or basal insulin 1, 5
For patients already on dual therapy, progressing to triple therapy by adding a third agent from a different class may be necessary 1, 2, 6

The American Diabetes Association recommends aiming for an HbA1c <7.0% to reduce microvascular complications, but less stringent goals may be appropriate for patients with limited life expectancy or advanced complications 1, 3, 4

Re-evaluating HbA1c in 3 months after treatment intensification is recommended to assess the effectiveness of therapy 1, 2
More frequent monitoring of blood glucose is required for patients started on insulin 5, 7

The Academy of Nutrition and Dietetics recommends reinforcing lifestyle interventions, including dietary modifications, regular physical activity, and weight management, as the foundation of diabetes management even when intensifying pharmacotherapy 1, 2, 6, 8

The American Heart Association recommends SGLT2 inhibitors and GLP-1 receptor agonists as preferred add-on therapy due to their cardiovascular benefits and lower hypoglycemia risk 9
For patients with heart failure and diabetes, an HbA1c target range of 7% to 8% is suggested, as both very high (>8%) and very low (<6%) HbA1c levels are associated with increased mortality 9

Insulin therapy should be strongly considered for patients with HbA1c significantly elevated above 8.5%, especially approaching or exceeding 10% 10
Patients with advanced chronic kidney disease and HbA1c >8.5% have a significantly higher risk of mortality (hazard ratio 1.4) compared to those with HbA1c in the 5-6% range 10
Less stringent glycemic targets (HbA1c up to 8-8.5%) may be appropriate for elderly patients, those with limited life expectancy, or patients with advanced complications 9

Failing to consider patient-specific factors when selecting medications can lead to increased risk of adverse effects 9
Setting overly aggressive HbA1c targets (<7%) in elderly patients or those with significant comorbidities may increase hypoglycemia risk without providing substantial benefit 9

When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding adjunctive therapy becomes more appropriate than continuing to escalate basal insulin alone, as further escalation risks "overbasalization" with clinical signals including hypoglycemia and high glucose variability, according to the American Diabetes Association 11
Jardiance dose escalation offers a complementary mechanism of action to existing insulin therapy, providing insulin-independent glucose lowering, as noted by the American College of Physicians 12

With Jardiance dose escalation from 10 mg to 25 mg, expect an additional HbA1c reduction of approximately 0.3-0.5%, which should bring the patient closer to the target HbA1c of <7% for most adults with type 2 diabetes, as recommended by the American Diabetes Association 11, 13

The American Diabetes Association recommends avoiding continuing to escalate insulin doses beyond 0.5-1.0 units/kg/day without addressing the need for adjunctive non-insulin therapy, to minimize the risk of hypoglycemia and weight gain 11